Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)

World News: . []

ANN ARBOR Mich Sept 13 2017 GLOBE NEWSWIRE -- Phrixus Pharmaceuticals Inc (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy and heart failure today announced that the first patient with DMD completed 15-mont h of tr...

More news and information about Phrixus Pharmaceuticals, Inc.

Published By:

Globe Newswire: 14:00 GMT Wednesday 13th September 2017

Published: .

Search for other references to "phrixus" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers